anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a storage container for a dental adhesive which can smoothly perform with high reproducibility a stable dripping operation and a fine dripping work such as rigorous dripping of a dripping amount, and can also suppress expansion of the adhesive stored inside due to a temperature raise when using the dental adhesive.  <P>SOLUTION: The storage container 10 for a dental adhesive includes a cylindrical container 11 capable of storing a liquid such as an adhesive. A discharge port 12 communicated with the outside is provided on one end side of this container 11, and the other end side of the container 11 is closed by a bottom wall 14. A tail part 13 protruding from this bottom wall 14 toward the opposite side of the discharge port 12 is formed. When dripping the liquid, neighborhood of the discharge port 12 can be supported by the thumb and index finger like handling writing implements such as a pencil. Since the tail part 13 can be supported near the root of the index finger, the stability of the holding state of the storage container 10a and the dripping state are excellent. Accordingly, rigorous dripping of a prescribed amount can be quickly and smoothly performed, and furthermore heat conduction to the liquid stored inside and its temperature raise can be suppressed.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention relates to a nucleoprotein comprising ribonucleic acid (RNA) and a viral protein containing more than 20% RNA (mass:mass). This RNA is contained within a virus-like structure that protects it from degradation. Moreover, this nucleoprotein simultaneously activates the innate immunity receptors TLR3, TLR2, TLR7, TLR8 and TLR9. The invention also relates to the use of said nucleoprotein for producing medicaments that enhance anti-infectious, anti-tumor, or anti-allergic responses, or for activating and training innate immunity in the prevention or treatment of infectious or allergic processes. This nucleoprotein can be used in treatments combined with other drugs. The invention further relates to the use of the nucleoprotein for producing an adjuvant or a carrier of vaccine antigens, to the pharmaceutical formulation comprising the nucleoprotein, and to a kit for the mucosal administration thereof.
Subjects will undergo Prospera testing in accordance with the institution's Control Group EMB surveillance standard of care schedule, which is expected to be approximately every other week months 2 and 3, then monthly through months 4 through 6, then every 1-3 months during months 7 through 12. Prospera test results will be provided to investigators. Prospera cfDNA level \< 0.15 % will be interpreted as negative, and screening EMB will be omitted. EMB will be performed for cfDNA level ≥ 0.15 %. At any time, the clinical team may perform for cause EMB for standard clinical indications (e.g., evidence of graft failure) as per the treating team's discretion.
Valsartan

Exforge HCT can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Exforge HCT as soon as possible [see Use in Specific Populations (8.1)]. 

Hydrochlorothiazide

Thiazides cross the placenta, and use of thiazides during pregnancy is associated with fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.
OBJECTIVE: The study aimed to translate, culturally adapt, and test the psychometric properties of the Musculoskeletal Pain Intensity and Interference Questionnaire for Musicians (MPIIQM) in an Italian population of professional and amateur musicians.
METHODS: The translation and cultural adaptation process followed international guidelines, while the reliability and validity of the questionnaire were assessed against the COSMIN checklist. The internal consistency was calculated using Cronbach's alpha (a) coefficient. Construct validity was analyzed using exploratory factor analysis (EFA) with principal axis factoring (PAF) extraction. The sample adequacy and data suitability were assessed through the Kaiser-Meyer-Olkin (KMO) and Bartlett's sphericity tests, respectively. Concurrent validity was analyzed by assessing Pearson's correlation coefficient with the Italian version of the Musculoskeletal Health Questionnaire (MSK-HQ-I). Finally, the cross-cultural validity was investigated by analyzing score differences between amateur and professional musicians, and differences based on musical practice habits.
RESULTS: The tool was administered to 311 subjects recruited from across Italy. The MPIIQM-IT was found to have high levels of internal consistency for the entire tool and each of the two subscales (Cronbach's a = 0.875, 0.877, and 0.845, respectively). The recruited sample was found to be adequate (KMO = 0.810) and the data suitable (C2 = 341.040, p < 0.001) for factor analysis, which produced 9 items contained in two main factors. Pearson's correlation coefficients showed a positive, statistically significant correlation between the MSK-HQ-I and the two subscales of the MPIIQM-IT with p < 0.01. Analysis of Student's t-test for independent samples and the ANOVA test for continuous variables showed statistically significant differences between male and female, professional and non-professional musicians, and conservatory and non-conservatory students.
CONCLUSIONS: The MPIIQM-IT is a valid and reliable tool, useful for investigating the presence of pain and playing-related musculoskeletal disorders (PRMDs) in both professional and non-professional musicians.
Scott, BR, Marston, KJ, Owens, J, Rolnick, N, and Patterson, SD. Current implementation and barriers to using blood flow restriction training: Insights from a survey of allied health practitioners. J Strength Cond Res 38(3): 481-490, 2024-This study investigated the use of blood flow restriction (BFR) exercise by practitioners working specifically with clinical or older populations, and the barriers preventing some practitioners from prescribing BFR. An online survey was disseminated globally to allied health practitioners, with data from 397 responders included in analyses. Responders who had prescribed BFR exercise ( n = 308) completed questions about how they implement this technique. Those who had not prescribed BFR exercise ( n = 89) provided information on barriers to using this technique, and a subset of these responders ( n = 22) completed a follow-up survey to investigate how these barriers could be alleviated. Most practitioners prescribe BFR exercise for musculoskeletal rehabilitation clients (91.6%), with the BFR cuff pressure typically relative to arterial occlusion pressure (81.1%) and implemented with resistance (96.8%) or aerobic exercise (42.9%). Most practitioners screen for contraindications (68.2%), although minor side effects, including muscle soreness (65.8%), are common. The main barriers preventing some practitioners from using BFR are lack of equipment (60.2%), insufficient education (55.7%), and safety concerns (31.8%). Suggestions to alleviate these barriers included developing educational resources about the safe application and benefits of BFR exercise ( n = 20) that are affordable ( n = 3) and convenient ( n = 4). These results indicate that BFR prescription for clinical and older cohorts mainly conforms with current guidelines, which is important considering the potentially increased risk for adverse events in these cohorts. However, barriers still prevent broader utility of BFR training, although some may be alleviated through well-developed educational offerings to train practitioners in using BFR exercise.
A process for the production of a dental prosthesis comprises disposing a paste or viscous solution which polymerizes at room temperature or a slightly elevated temperature between a model and a base plate, pressing the base plate so that the paste or solution fills all the interstices between the base plate and the model and allowing the paste or solution to polymerize to form a lining on the base plate.  A model is prepared after taking an impression of the jaw.  The base plate is cut to the shape of the model from a sheet of suitable synthetic resin material.  The base plate is softened by boiling water and shaped to the model, the shape being made permanent by immersing in cold water.  A suitable lining mixture is then applied to the tissue side of the base plate which is then pressed on the model so that the mixture fills the interstices between the base plate and the model.  The lining mixture polymerizes at room temperature in a short time. Teeth of porcelain or polymethyl methacrylate are affixed to the plate using the same mixture as for the lining.  The polymerized parts require finishing and polishing. In cutting the base plate a pattern in tin foil cut to the model may be used.  In shaping the base plate to the model the hands may be protected from the heat by placing a foil of cellulose acetate over the base plate. The plastic mixture may be shaped in the mouth of the patient which is protected by greasing with "Vaseline" (Registered Trade Mark).  The base plate is made of copolymers of methyl methacrylate and butadiene or its derivatives, methyl methacrylate or vinyl chloride and acrylates or methacrylates the alcohol radical of which contains more than three carbon atoms or polymethyl methacrylate plasticized with benzyl-butyl adipate or suitable phthalates.  The lining mixture is made from mixtures or viscous solutions of polymeric and monomeric vinyl compounds such as polymeric and monomeric methacrylate or solutions of polymethyl methacrylate in methyl methacrylates containing Redox systems. Styrene, acrylonitrile or compounds having at least two polymerizable double bonds, e.g. divinyl benzene or ethylene glycol dimethacrylate or polyfunctional vinyl compounds may be added to the materials of the base plate.  Specification 558,470 is referred to.
Patients with a previously placed HydroMARK T3 coil clip or a clip made by another manufacturer and will have a HydroMARK Plus clip placed during the scout localization procedure for this study. Breast surgeons will perform retrieval and then complete a satisfaction survey to compare the two clips.
Cardiomyopathy including cardiac failure, congestive heart failure, ejection fraction decreased, diastolic dysfunction, or right ventricular dysfunction can occur with YONDELIS. In Trial ET743-SAR-3007, a significant decrease in LVEF was defined as an absolute decrease of ≥15% or below the lower limit of normal with an absolute decrease of ≥5%. Patients with a history of New York Heart Association Class II to IV heart failure or abnormal left ventricular ejection fraction (LVEF) at baseline were ineligible. In Trial ET743-SAR-3007, cardiomyopathy occurred in 23 patients (6%) receiving YONDELIS and in four patients (2.3%) receiving dacarbazine. Grade 3 or 4 cardiomyopathy occurred in 15 patients (4%) receiving YONDELIS and 2 patients (1.2%) receiving dacarbazine; cardiomyopathy leading to death occurred in 1 patient (0.3%) receiving YONDELIS and in none of the patients receiving dacarbazine. The median time to development of Grade 3 or 4 cardiomyopathy in patients receiving YONDELIS was 5.3 months (range: 26 days to 15.3 months). 

Patients with LVEF < lower limit of normal, prior cumulative anthracycline dose of ≥300 mg/m2, age ≥65 years, or a history of cardiovascular disease may be at increased risk of cardiac dysfunction. Assess LVEF by echocardiogram (ECHO) or multigated acquisition (MUGA) scan before initiation of YONDELIS and at 2- to 3-month intervals thereafter until YONDELIS is discontinued. Discontinue treatment with YONDELIS based on severity of adverse reaction [see Dosage and Administration (2.3)].
Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

The NOMID study included 36 pediatric patients: 13 below 2 years, 18 between 2 and 11 years, and 5 between 12 and 17 years of age. A subcutaneous KINERET starting dose of 1–2 mg/kg/day was administered in all age groups. An average maintenance dose of 3–4 mg/kg/day was adequate to maintain clinical response throughout the study irrespective of age but a higher dose was, on occasion, required in severely affected patients. The prefilled syringe does not allow doses lower than 20 mg to be administered.

Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

The study in DIRA patients included 9 pediatric patients (ages 1 month to 9 years at start of KINERET treatment). Most patients received a starting dose of 1 to 2 mg/kg/day. Doses up to 7.5 mg/kg/day were given. The prefilled syringe does not allow doses lower than 20 mg to be administered.

Juvenile Rheumatoid Arthritis (JRA)

The safety and effectiveness of KINERET in the treatment of pediatric patients with Juvenile Rheumatoid Arthritis (JRA) have not been established. KINERET was studied in a single randomized, blinded multi-center trial in 86 patients with polyarticular course JRA; ages 2-17 years receiving a dose of 1 mg/kg subcutaneously daily, up to a maximum dose of 100 mg. The 50 patients who achieved a clinical response after a 12-week open-label run-in were randomized to KINERET (25 patients) or placebo (25 patients), administered daily for an additional 16 weeks. A subset of these patients continued open-label treatment with KINERET for up to 1 year in a companion extension study. An adverse event profile similar to that seen in adult RA patients was observed in these studies. These study data are insufficient to demonstrate efficacy and, therefore, KINERET is not recommended for pediatric use in JRA.
PROBLEM TO BE SOLVED: To provide a method for producing a solution having bactericidal, bacteriostatic and deodorizing properties by mixing, spraying, immersion and coating and further improving skin water retaining properties by spraying and coating the skin surface of human body with the solution. SOLUTION: This method comprises adding a proper amount of phosphatidylcholine to purified water, heating the mixture, emulsifying the heated mixture by shaking, adding a proper amount of a fatty acid to the emulsion, emulsifying the emulsion by shaking, then adding a proper amount of vitamin A to the emulsion, emulsifying the emulsion by shaking, adding a proper amount of a solution of ferrous chloride and a proper amount of a solution of ferric chloride to the emulsion by shaking and finally diluting the emulsion. The formulation volume ratio is 1 pt.vol. of the fatty acid, 5 pts.vol. of vitamin A 0-2.5, 10 pts.vol. of 1×106 mol/l aqueous solution of ferrous chloride and 10 pts.vol. of 1×106 mol/l aqueous solution of ferric chloride.
A gordon euryale stem bath powder for removing heat to promote salivation and a production method thereof are disclosed. The bath powder comprises a medicinal powder packet and a spice packet. The medicinal powder is prepared from the following raw materials, by weight, 35-45 parts of gordon euryale stem, 10-16 parts of Pileostegia viburnoides Hook. f. et Thoms., 10-16 parts of Isodon longitubus, 5-8 parts of fiveleaf chastetree wood, 5-8 parts of pleioblastus amarus, 5-8 parts of oil rape seed, 5-8 parts of horse chest nut, 3-6 parts of small-leaved lemmaphyllum, 3-6 parts of Psychotria serpens, 3-6 parts of sophora viciifolia and 3-6 parts of phyllan lhus mat shilllirae. The spice packet is prepared from the following ingredients, by weight, 10-12 parts of rose, 8-10 parts of China rose, 6-8 parts of seville orange flower, 3-5 parts of lilac and 3-5 parts of lavender. The production method comprises the following main steps: (1) manufacturing steps of the medicinal powder packet include: A, pretreatment of the raw materials; B, immersion, drying by evaporation, cutting and baking; C, centrifugal separation and mixing of solutions; E, concentration and drying; (2) manufacturing of the spice packet; and (3) packaging of the medicinal powder packet and the spice packet to prepare the finished product. The gordon euryale stem bath powder for removing heat to promote salivation has effects of clearing deficient heat, producing body fluid, clearing heat, eliminating vexation and regulating qi by alleviation of mental depression if taken for a long time.
Prospective participants will be contacted by telephone to confirm eligibility, explain the study protocol, and obtain informed consent. An in-person or videoconference assessment will be used to administer baseline PHQ-9 to confirm enrolment criteria and will be asked questionnaire to gather demographic information. Participants will then be provided with an email link to access the Online Psycho Therapy Tool (OPTT). PHQ-9 will be collected again at the mid-point (4 weeks) and after completing the program through OPTT. Caregivers will be invited to assist the participant if required in completing Ger-iPST modules, and weekly telephone support calls by a research assistant will be provided to assist with any difficulty navigating technical aspects of the Ger-iPST platform.
This research study will look at the outcome benefits of providing cognitive rehabilitation, utilizing the group process. Criteria for selecting the appropriate participants, group format and structure, as well as use of standardized assessments. The assessments used: Three Step Calendar Approach, (Sohlberg and Mateer) Satisfaction With Life scale (SWLS), Community Integration Questionnaire (CIQ), Independent Living Scale, and the Vocational Independence Scale. The group setting provides an atmosphere to work on building communication skills through peer feedback and to develop psychological coping strategies. Techniques such as the problem solving format and a calendar system. Analysis and outcomes of 17 past group participants were analyzed supporting cognitive rehabilitation in the group setting.

Of the 20 participants, 3 chose not to be included.
The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode.
Cardiovascular diseases (CVDs) linked to atherosclerosis remains the leading cause of death worldwide. Atherosclerosis is primarily caused by the accumulation of oxidized forms of low density lipoprotein (LDL) in macrophages (MΦs) in the subendothelial layer of arteries leading to foam cell and fatty streak formation. Many studies suggest that LDL that is modified by myeloperoxidase (MPO) is a key player in the development of atherosclerosis. MΦs can adopt a variety of functional phenotypes that include mainly the proinflammatory M1 and the anti-inflammatory M2 MΦ phenotypes which are both implicated in the process of atherogenesis. In fact, MΦs that reside in atherosclerostic lesions were shown to express a variety of phenotypes ranging between the M1- and M2 MΦ types. Recently, we pointed out the involvement of MPO oxidized-LDL (Mox-LDL) in increasing inflammation in MΦs by reducing their secretion of IL-10. Since little is known about Mox-LDL-mediated pro-atherosclerostic responses in MΦs, our study aimed at analyzing the in vitro effects of Mox-LDL at this level through making use of the well-established model of human THP-1-derived Mφs. Our results demonstrate that Mox-LDL has no effect on apoptosis, reactive oxygen species (ROS) generation and cell death in our cell model; yet, interestingly, our results show that Mox-LDL is significantly engulfed at a higher rate in the different MΦ subtypes supporting its key role in foam cell formation during the progression of the disease as well as previous data that were generated using another primary MΦ cell model of atherosclerosis.
PURPOSE:To efficiently obtain the subject extract in high yield by hydrolyzing the root of Rumex japonicus with an acid followed by extraction with an organic solvent. CONSTITUTION:Firstly, the root or the whole grass of Rumex japonicus is air-dried or hot air-dried and ground into dry powder. Second, 50-200 pts.wt. of water is added to 100 pts.wt. of the dry powder followed by addition of an acid solution (the acid concentration is adjusted to 0.1-30wt.%) and then agitation at 10-50 deg.C for 30-60min to carry out hydrolysis. Third, 200-100 pts.wt. of an organic solvent (pref. hexane) is added to the system followed by continuing further agitation for 30-60min. The system is then allowed to stand and the organic solvent layer separated is taken and the solvent is distilled off, thus obtaining the objective Rumex japonicus extract, which can be used either directly or in the form of an organic solvent (e.g. ethanol, glycerol) solution or powder or tablet through the addition of an excipient such as lactose.
The intensity of application is important for foam rollers. For intensity, the intensity of the pressure will be determined by a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort) and applied at the end of each session.
Lymphocyte decline, particularly the depletion of NK cells, is a prominent feature of immunosuppression following severe tissue injury, heightening the susceptibility of severe trauma patients to life-threatening infections. Previous research indicates that the reduction in the number of NK cells is closely associated with the process of cell death. Nonetheless, the precise mechanism of NK cell death remains unknown. Here, we discovered that following severe traumatic injury, NK cells undergo several cell death pathways, dominated by apoptosis and pyroptosis with coexistence of necrotic cell death, immunogenic cell death, ferroptosis, and autophagy. These NK cells with different paradigms of death have diverse cytokine expression profiles and diverse interactions with other immune cells. Further exploration revealed that hypoxia was strongly associated with this diverse paradigm of NK cell death. Detailed investigation of paradigms of cell death may help to enhance comprehension of lymphopenia post-severe trauma, to develop new strategy in preventing immunosuppression, and then to improve outcome for severe trauma population.